DOCSLIB.ORG

Marijuana and Health. Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Marijuana and Health. Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy DOCUMENT RESUME ED'218 568 CG 016 068 TITLE Marijuana and Health. Report of a Study by a Committee of the Institute of Medicine, Division of Health Sciences Policy. INSTITUTION Institute of Medicine (NAS), Washington, D.C. -SPONS AGENCY National Institutes of Health (DHHS), Bethesda, Md. ''REIBORT NO ISBN-0-309-03236-9 PUB DATE - 82 -CONTRACT NIH-N01-0D-0-2114 NOTE 203p. AVAILkBLE FROMNational Academy Press, 2101 Constitution Avenue, N.W., Washington, DC 20418. EDRS PRICE MFO1 Plus Postage. PC iot Available from EDRS. DESCRIPTORS *Drug Abuse; *Drug Use; Literature Reviews; *Marihuana; Medical Evaluation;. Medical Research; *Pharmacology; *Physical Health;, Research Needs; Research Utilization ABSTRACT- , This report, Written for the general public, presents the results tif-a-15=M6fith study of-the health-relate-a effects of Marijuana. The introduction describes the goalX and procedure for the Xttdy, including the composition of the 22-member steering committee and its functions, and ,'the sources of inforMation used for the study, i.e., published scientific literature from 1975 forward, and, information and opinions solicited from the public and professional grOupt--;-Chipter:1 reviews what-ia -known about the chemistry sand pharmacology of marijuana. Chapter 2 deals with'the epidemiology and -demography' Of the use of marijuana in the United States. The next three chapters discuss the effects of marijuana on cells, tissues, organs; and biological systems. Chapter 6 deals with behavioral and ptyChosocial-effects: Chapter 7 discusses the present status of ___IsXrijuana-as a therapeutic agent-Chapter 8 describes and analyzes the federla research program on marijuana. A summary includes the principal findings and conclusions of the study, together with stggistions for future research. A glossary of terms for marijuana-related products and appendices with additional study information are included.-(Author/MCF) *********************************************************************** * Reproductions supplied by EDRS are the best that can be made * * from the original document. * ***************i****************************************************** HARD' COPY NOT AVAILABLE Marijuana and Health 'Report of a Study by a Committee of the INSTITUTE OF MEDICINE Division of Health-Sciences Policy DEPARTMENT OF EDUCATION "PERMISSION TO REPRODUCE THIS NATIONAL INSTITUTEOF EDUCATION MATERIAL IN MICROFICHE ONLY EDUCATIONAL RESOURCES INFORMATION HAS BEEN GRA ED CENTER (ERICI LI The document has been reproduced as teceiyedizotnte_Pe/son or organization onginatign. )(Minor changes have been made to improve reproduction quality. TO THE EDUCATIONAL RESOURCES Points of view or opimonsstated in this docu INFORMATION CENTER (ERIC)." meet do not necessarily represent official NIE position or policy. CO NATIONAL ACADEMY PRESS q) Washington, D.C. 1982 C) '.O O C.) NOTICE The project that is the subject of this reportrwa8 approved by the Governing Board of the National Research Couhcil, whose members are drawn from the Councils of the NationaViicademy of. Sciences, the National Academy of Engineering, and'the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance. This report has een reviewect.by a group other than the authors according to p ocedures approved byra Report Review Committee consisting ofembers of the National Academy of Sciences, the National Acad my of Engineering, and the Institute of Medicine. The Institutof Medicine was chartered in 1970 by the National Academy of S iences to enlist distinguished members of the _appropriaterOfessions in the examination of policy matters pertaining tthe health of the public. In this;' the Institute acts under both e Academy's 1863 Congressional charter responsibility to be an advis r to the federal government, and its own initiative in identifying issues of medical care, research, and education. This study was suppOrted by the National Institutes of Health, Contract No. 140170D-0-2114. International Standard Book Number 0-309-03236-9 Library of Congress Catalog Card Number 81-86534 Available from: NATIONAL ACADEMY PRESS 2101 Constitution Ave., N.W. Washington, D.C. 20418 Printed in the United States of America COMMITTEF TO STUDY THE HEALTH-RELATED EFFECTS OF CANNABIS.AND ITS DERIVATIVES Arnold S. Reiman, Chairman Editor The New England Journal of Medicine Konrad E. Bloch Irwin Feinberg Professor Professor of Psychiatry Department of Chemistry University of California, Harvard University San Francisco,and Veterans Administration Medical Barton Childs Center, San Francisco Professor, of Pediatrics and Biology Alfred P. Fishman The Johns Hopkins University Professor of Medicine School of Medicine Director Cardiovascular Pulmonary Division Michael I. Cohen Hospital of the University Chairman 'and Professor of Pennsylvania Department of Pediatrics Albert Einstein College Beatrix Hamburg of'Medicine Apsociate_Professor-of-Psychiatry--- Montefiore Hospital and Dppaitment of Psychiatry and Medical Center Department of Social Meditine and Health Policy P. B. Dews arvard Medical School Professor of Psychiatry and Psychobiology H. Carl Haywood Laboratory of Psychobiology Trofessor of Psychology Harvard Medical School I. and Neurology pirector ,Edward F. Domino The John Fe Kennedy Center Professor for Research on Education Department of Pharmacology and Human Development University of Michigan Vanderbilt University Robert B. Edgerton Reese T. Jones Professor Professor of Psychiatry Departments of Psychiatry Langley Poeter Psychiatric and Anthropology Institute University of California, University of California, Los Angeles, ' San Francisco Daniel D% FedeFilan Harold Kalant Dean for Students and Alumni Professor Harvard Medical School Department of Pharmacology University of Toronto iii Denise Kandel Norton Nelson Professor of Public Health Professor of Environmental Department of Psychiatry Medicine ' Columbia University and New York University New York State Psychiatric Medical,Center Institute Charles P. O'Brien Barbara M. Korsch Professor of Psychiatry Professor of Pediatrics University of Pennsylvania and Head School of Medicine and" Division of General Pediatrics Philadelphia Veterans Adminis- Children's Hospital of // tration Medical Center Los Angeles University of Southern California Sheldon J. Segal School of Medicine Director Population'Sciences Division Robert Y. Moore Rockefeller Foundation Professor and-Chairman _Department of Neurology Paul D. Staley State University/of New York Professor at Stony Brook Department of Medicine University of Pennsylvania Robert F. Murray, Jr. School of Medicine Professor of Pediatrics, Medicine and Oncology Chief, Division of Medical Genetics ,Department of Pediatrics and Child Health College of Medicine Howard University iv INSTITUTE OF MEDICINE Frederick C. Robbins President Study Staff Enriqueta C. Bind, Director, Division of Health Sciences Policy Linda S. Dujack, Study Director Kathryn G-iKihg, Research Associate Caren M. Carney, Research Associate Allyn M. Mortimer, Research Assistant Roszel S. Thomsen II, Research Assistant Linda A. DePugh, Administrative Secretary Constance V. Shuck, Administrative Secretary With the collaboration of the Director of the Division of Mental ---HeilthAffd-Beh&VWfal-Medidine, Fkedric Solomon, and the assistance of Institute of Medicine staff members Barbara Fi ).ner,Barbara Mandula, and Robert Field. Consultants Henry D. Abraham, Harvard University Richard E. Belleville, Privitte Consultant Kevin Fehr, Addiction Research Foundation Herbert Moskowitz, Southern CaliforniaResearch Institute Wendy Nelson, University of Pennsylvania ;Oakley S. Ray, Veterans Administration dical Center Brian L. Strom, University of Pennsylvania v 0 "Study of the Health-Related Effects of Cannabis and Iti Derivatives PANELS CardiovascUlar and Respiratory Issues Alfred P. Fishman*, Chairman Brian F. Hoffman Gerard M. Turino Professor and Chairman Professor of Medicine Department of Pharmacology Department of M dicine Columbia University College Columbia Unive sity College of Physicians and Surgeons of Physicians and Surgeons / Jerome I.0 Kleinerman Chairman Department of Pathology Mount Sinai:School of Medicine Neurobiological Issues Irwin Feinberg*, Chairm EdWard F. DoMino* A. Edwa d Maumenee Profess r of Ophthalmology H. Craig Hellcr, Wilmer/Institute Associate Professor of. Biology Johns Hopkins Hospital Department of Biological Sciences StanfOrd University Robert Moore* Reese, T. Jones* Charles P. O'Brien* Harold Kalant* Irwin H. Krakoff Director 'Vermont Regional Cancer Center *Committee member. vi B navioral, Psychosocial, and Epidemiologic Issues Ch rles P. O'Brien* and H. Carl Haywood*,,Co-Chairmen Michael I. Cohen* Denise Kandel* Robert B. dgerton* BarbaraM. Korsch* Beatrix Hburg* Paul D. Stolley*, Reese T. J nes* Reproductive and Fetal Issues Daniel D. Federman*, Chairman F. Clarke raser Norton Nelson* Director o .Medical Genetics Montreal ildren's Hospital Sheldon Segal* 111 Genetic, bncogenic, and Cytogenetic Issuep Barton Childs*,Chairman Arthur DOBloom Robert F. Murray, Jr:* Professor of Pediatrics and of Human Genetics and Development Norton Nelson* Director,;ClinicarGenetics Columbia University College of Physicians and Surgeons Dietrich Hoffmann: Associate,Direct:Or Naylor Dana Institute for Disease Prevention Cell Biology, Pharmacology, and immunologicalIssues P. B. Dews*, Chairman Konrad E. Bloch* Peter H. Schur Professor of Medicine
Load more

Recommended publications
  • Non-Steroidal Drug-Induced Glaucoma MR Razeghinejad Et Al 972
    Eye (2011) 25, 971–980 & 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11 www.nature.com/eye 1,2 1 1 Non-steroidal drug- MR Razeghinejad , MJ Pro and LJ Katz REVIEW induced glaucoma Abstract vision. The majority of drugs listed as contraindicated in glaucoma are concerned with Numerous systemically used drugs are CAG. These medications may incite an attack in involved in drug-induced glaucoma. Most those individuals with narrow iridocorneal reported cases of non-steroidal drug-induced angle.3 At least one-third of acute closed-angle glaucoma are closed-angle glaucoma (CAG). glaucoma (ACAG) cases are related to an Indeed, many routinely used drugs that have over-the-counter or prescription drug.1 Prevalence sympathomimetic or parasympatholytic of narrow angles in whites from the Framingham properties can cause pupillary block CAG in study was 3.8%. Narrow angles are more individuals with narrow iridocorneal angle. The resulting acute glaucoma occurs much common in the Asian population. A study of a more commonly unilaterally and only rarely Vietnamese population estimated a prevalence 4 bilaterally. CAG secondary to sulfa drugs is a of occludable angles at 8.5%. The reported bilateral non-pupillary block type and is due prevalence of elevated IOP months to years to forward movement of iris–lens diaphragm, after controlling ACAG with laser iridotomy 5,6 which occurs in individuals with narrow or ranges from 24 to 72%. Additionally, a open iridocorneal angle. A few agents, significant decrease in retinal nerve fiber layer including antineoplastics, may induce thickness and an increase in the cup/disc ratio open-angle glaucoma.
    [Show full text]
  • Abcd (Ipratropium Bromide and Albuterol Sulfate) Inhalation Aerosol
    ATTENTION PHARMACIST: Detach “Patient’s Instructions for Use” from package insert and dispense with the product. Combivent® abcd (ipratropium bromide and albuterol sulfate) Inhalation Aerosol Bronchodilator Aerosol For Oral Inhalation Only Rx only Prescribing Information DESCRIPTION COMBIVENT Inhalation Aerosol is a combination of ipratropium bromide (as the monohydrate) and albuterol sulfate. Ipratropium bromide is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo[3.2.1] octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl­ 8-(1-methylethyl)-, bromide monohydrate, (3-endo, 8-syn)-: a synthetic quaternary ammonium compound chemically related to atropine. Ipratropium bromide is a white to off-white crystalline substance, freely soluble in water and methanol, sparingly soluble in ethanol, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons. The structural formula is: + N OH Br­ . H O H 2 O O C20H30BrNO3•H2O ipratropium bromide Mol. Wt. 430.4 Albuterol sulfate, chemically known as (1,3-benzenedimethanol, α'-[[(1,1dimethylethyl) amino] methyl]-4-hydroxy, sulfate (2:1)(salt), (±)- is a relatively selective beta2-adrenergic bronchodilator. Albuterol is the official generic name in the United States. The World Health Organization recommended name for the drug is salbutamol. Albuterol sulfate is a white to off-white crystalline powder, freely soluble in water and slightly soluble in alcohol, chloroform, and ether. The structural formula is: Reference ID: 2927161 OH NH * . H2SO4 OH OH 2 (C13H21NO3)2•H2SO4 albuterol sulfate Mol. Wt. 576.7 Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol contains a microcrystalline suspension of ipratropium bromide and albuterol sulfate in a pressurized metered-dose aerosol unit for oral inhalation administration.
    [Show full text]
  • 2020 International Narcotics Control Strategy Report
    United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2020 INCSR 2020 Volume 1 Table of Contents Table of Contents Common Abbreviations ..................................................................................................................................... iii International Agreements.................................................................................................................................... v INTRODUCTION ..................................................................................................................................... 1 Legislative Basis for the INCSR ......................................................................................................................... 2 Presidential Determination ................................................................................................................................. 7 Policy and Program Developments .................................................................................................... 12 Overview ......................................................................................................................................................... 13 Methodology for U.S. Government Estimates of Illegal Drug Production .......................................................... 18 Parties to UN Conventions ..............................................................................................................................
    [Show full text]
  • Combatting Drug Abuse, and Related Crime
    If you have issues viewing or accessing this file contact us at NCJRS.gov. "0 UNITED NATIONS SOCIAL DEFENCE RESEARCH INSTITUTE· Publication No. 21 COMBATTING DRUG ABUSE, AND RELATED CRIME ". o FrateiU Palombi. Editori Rome, July 1984 . UNSDRI UNITED NATIONS SOCIAL DEFENCE RESEARCH INSTITUTE Publication No. 21 COMBATTING DRUG "ABUSE AND RELATED CRIME: Comparative research on the effectiveness o/socio-Iega! preventive and control measures in different countries on the interaction between criminal behaviour and drug abuse Funded by the UNITED NATIONS FUND FOR DRUG ABUSE CONTROL by Francesco Bruno M.D. ft~~i1l Fratelli Palombi Editori Rome, July 1984 97289 U.S. Department of Justlce National Institute of Justice This document has been reprodu~ed exaclly as received from the person or organization originating it. Points of view or opinions stated in this document are those of the authors and do not necessarily represent the official position or policies of the Nallonai Institute of Justice. Permission to reproduce this copyrighted material has been granted,by • • Un~ted Nat~ons Soc~al Befence Research Inst~tute (UNSURT) to the National Criminal Justice Reference Service (NCJRS). Further reproduc!ion outside of the NCJRS system requires permis­ sion of the copyright owner. Copyright © UNSDRI TshBeNUru8'ted Nations Social Defence Research Institute 1984 I 8 -7621-826-2 ' Extracts from this publication b d . condition that the source is indk:re/ repro uced wIthout authorization on TABLE OF CONTENTS Page Foreword ............. K~.G·.~~.~.~: ...... :...... 3 Chapters . APR 3~ 1965 I. IntroductIon ............................... 7 II. The researchJ.l\. C~·tH iU '1'i!'O'N S' ......
    [Show full text]
  • Article 22 Regulation for Restriction of Synthetic Drugs
    ARTICLE 22 REGULATION FOR RESTRICTION OF SYNTHETIC DRUGS SECTION 22.1 AUTHORITY This regulation is promulgated under the authority granted to the Needham Board of Health under Massachusetts General Laws Chapter 111, Section 31 which states that “boards of health may make reasonable health regulations”. SECTION 22.2 PURPOSE The Needham Board of Health has found that synthetic marijuana, consisting of plant or other material treated with various chemicals or other synthetic substances not approved for human consumption, may be marketed and sold as herbal incense in the greater Boston area, although they are being used in the same manner and for the same purposes as scheduled drugs. In addition, the use of these products has become particularly popular among teens and young adults. Based on information and reports from hospitals, emergency room doctors, and police agencies, individuals who use these products experience dangerous side effects including convulsions, hallucinations, and dangerously elevated heart rates. This is evidence that synthetic marijuana products are harmful if inhaled or consumed, and present a significant public health danger. These synthetic compounds and others have a high potential for abuse and lack of any accepted medical use, these dangerous products, while not approved for human consumption, are marketed and sold in a form that allows for such consumption, putting at risk the individuals who come into contact with them. Therefore, the Needham Board of Health adopts this regulation for the purpose and with the intent to protect the public health and safety of the Town of Needham and its residents from the threat posed by the availability and use of synthetic marijuana, synthetic stimulants, synthetic hallucinogens, and other dangerous products by prohibiting persons from trafficking in, possessing, and using them within the town.
    [Show full text]
  • Pharmacology of Ophthalmic Agents
    Ophthalmic Pharmacology Richard Alan Lewis M.D., M.S., PHARMACOLOGY FOPS PHARMACOKINETICS OF Professor, Departments of Ophthalmology, • The study of the absorption, OPHTHALMIC Medicine, Pediatrics, and Molecular distribution, metabolism, AGENTS and Human Genetics and excretion of a drug or and the National School of Tropical agent Introduction and Review Medicine Houston, Texas PHARMACOKINETICS Factors Affecting Drug Penetration Factors Affecting Drug Penetration into Ocular Tissues • A drug can be delivered to ocular tissue: into Ocular Tissues – Locally: • Drug concentration and solubility: The higher the concentration the better the penetration, • Surfactants: The preservatives in ocular • Eye drop but limited by reflex tearing. preparations alter cell membrane in the cornea • Ointment and increase drug permeability, e.g., • Viscosity: Addition of methylcellulose and benzalkonium and thiomersal • Periocular injection polyvinyl alcohol increases drug penetration by • pH: The normal tear pH is 7.4; if the drug pH is • Intraocular injection increasing the contact time with the cornea and altering corneal epithelium. much different, it will cause reflex tearing. – Systemically: • Lipid solubility: Because of the lipid rich • Drug tonicity: When an alkaloid drug is put in • Orally environment of the epithelial cell membranes, relatively alkaloid medium, the proportion of the uncharged form will increase, thus more • IM the higher lipid solubility, the more the penetration. • IV penetration. FLUORESCEIN FLUORESCEIN Chemistry Dosage ● C20H1205, brown crystal ● Adults: 500-750 mg IV ● M.W. 322.3 e.g., 3 cc 25% solution ● Peak absorption 485-500 nm. 5 cc 10% solution ● Peak emission 520-530 nm. ● Children: 1.5-2.5 mg/kg IV Richard Alan Lewis, M.D., M.S.
    [Show full text]
  • 2 Spice English Presentation
    Spice Spice contains no compensatory substances Специи не содержит компенсационные вещества Spice is a mix of herbs (shredded plant material) and manmade chemicals with mind-altering effects. It is often called “synthetic marijuana” because some of the chemicals in it are similar to ones in marijuana; but its effects are sometimes very different from marijuana, and frequently much stronger. It is most often labeled “Not for Human Consumption” and disguised as incense. Eliminationprocess • The synthetic agonists such as THC is fat soluble. • Probably, they are stored as THC in cell membranes. • Some of the chemicals in Spice, however, attach to those receptors more strongly than THC, which could lead to a much stronger and more unpredictable effect. • Additionally, there are many chemicals that remain unidentified in products sold as Spice and it is therefore not clear how they may affect the user. • Moreover, these chemicals are often being changed as the makers of Spice alter them to avoid the products being illegal. • To dissolve the Spice crystals Acetone is used endocannabinoids synhtetic THC cannabinoids CB1 and CB2 agonister Binds to cannabinoidreceptor CB1 CB2 - In the brain -in the immune system Decreased avtivity in the cell ____________________ Maria Ellgren Since some of the compounds have a longer toxic effects compared to naturally THC, as reported: • negative effects that often occur the day after consumption, as a general hangover , but without nausea, mentally slow, confused, distracted, impairment of long and short term memory • Other reports mention the qualitative impairment of cognitive processes and emotional functioning, like all the oxygen leaves the brain.
    [Show full text]
  • The Maritime Trade in Illicit Drugs
    THE MARITIME TRADE IN ILLICIT DRUGS: THE EXPERIENCE OF THE COASTAL MEMBER STATES OF O.E.C.D. Bjorn Robertstad Aune Thesis Submitted for the Ph.D. Degree University of London London School of Economics and Political Science 1989 UMI Number: U550164 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U550164 Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 T\\£S F 6&06 I X'cQ 1 13/ Lj-3iQ(a ABSTRACT The trafficking of illicit drugs by sea has become an industry comprised of many individual enterprises of variform size and organization. Seizure statistics for the 1980s indicate that 70% of the total quantity of drugs intercepted in the trafficking stage were inter­ dicted in the maritime sector or attributed to having been transported by sea. More significantly, it appears that only between 8 - 12% of the total volume of drugs trafficked are intercepted. The use of the sea­ borne modes of transport is the result of planetary geography which made the maritime medium one of only two ways by which drugs may enter several states.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmacology for Respiratory Care 1
    RESP-1340: Pharmacology for Respiratory Care 1 RESP-1340: PHARMACOLOGY FOR RESPIRATORY CARE Cuyahoga Community College Viewing: RESP-1340 : Pharmacology for Respiratory Care Board of Trustees: March 2020 Academic Term: Fall 2020 Subject Code RESP - Respiratory Care Course Number: 1340 Title: Pharmacology for Respiratory Care Catalog Description: General principles of pharmacology and calculations of drug dosages. Discussion of pharmacologic principles and agents used in treatment of cardiopulmonary disorders. Credit Hour(s): 2 Lecture Hour(s): 2 Lab Hour(s): 0 Other Hour(s): 0 Requisites Prerequisite and Corequisite RESP-1300 Respiratory Care Equipment and RESP-1310 Cardiopulmonary Physiology. Outcomes Course Outcome(s): A. Evaluate specific information on various categories of drugs. Objective(s): 1. Demonstrate an understanding of basic terminology for respiratory care pharmacology. 2. Identify the official drug publication in the U.S. 3. Identify four common sources of drug information. Course Outcome(s): B. Describe the basic principles of drug action emphasizing the pharmaceutical phase, pharmacokinetic phase and pharmacodynamic phase. Objective(s): 1. Identify the three phases involved in drug action. 2. Identify five different routes of administration and give advantages and disadvantages of each route. 3. Identify the four processes involved in the pharmacokinetics phase. 4. Identify the essential concepts involved with the interaction of a drug molecule with its target receptor site. 2 RESP-1340: Pharmacology for Respiratory Care Course Outcome(s): C. Calculate and interpret adult dosages for medications given by respiratory care practitioners. Objective(s): 1. Calculate dosages from percentage strength solutions. 2. Calculate the amount of solute per ml of solution given a ratio.
    [Show full text]
  • ENLON-PLUS (Edrophonium Chloride, USP and Atropine Sulfate, USP) Injection
    NDA 19-677/S-005 NDA 19-678/S-005 Page 3 ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection Rx only DESCRIPTION ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection, for intravenous use, is a sterile, nonpyrogenic, nondepolarizing neuromuscular relaxant antagonist. ENLON-PLUS is a combination drug containing a rapid acting acetylcholinesterase inhibitor, edrophonium chloride, and an anticholinergic, atropine sulfate. Chemically, edrophonium chloride is ethyl (m-hydroxyphenyl) dimethylammonium chloride; its structural formula is: Molecular Formula: C10H16ClNO Molecular Weight: 201.70 Chemically, atropine sulfate is: endo-(±)-alpha-(hydroxymethyl)-8-methyl-8-azabicyclo [3.2.1]oct-3-yl benzeneacetate sulfate (2:1) monohydrate. Its structural formula is: Molecular Formula: (C17H23NO3)2·H2SO4·H2O NDA 19-677/S-005 NDA 19-678/S-005 Page 4 Molecular Weight: 694.84 ENLON-PLUS contains in each mL of sterile solution: 5 mL Ampuls: 10 mg edrophonium chloride and 0.14 mg atropine sulfate compounded with 2.0 mg sodium sulfite as a preservative and buffered with sodium citrate and citric acid. The pH range is 4.0- 5.0. 15 mL Multidose Vials: 10 mg edrophonium chloride and 0.14 mg atropine sulfate compounded with 2.0 mg sodium sulfite and 4.5 mg phenol as a preservative and buffered with sodium citrate and citric acid. The pH range is 4.0-5.0. CLINICAL PHARMACOLOGY Pharmacodynamics ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is a combination of an anticholinesterase agent, which antagonizes the action of nondepolarizing neuromuscular blocking drugs, and a parasympatholytic (anticholinergic) drug, which prevents the muscarinic effects caused by inhibition of acetylcholine breakdown by the anticholinesterase.
    [Show full text]